We Offer Worldwide Shipping
Login Wishlist

Diphenhydramine hydrochloride

$87

Brand : BIOFRON
Catalogue Number : BN-O0025
Specification : 98%(HPLC)
CAS number : 147-24-0
Formula : C17H21NO.ClH
Molecular Weight : 291.8
PUBCHEM ID : 8980
Volume : 20mg

Available on backorder

Quantity
Checkout Bulk Order?

Catalogue Number

BN-O0025

Analysis Method

Specification

98%(HPLC)

Storage

2-8°C

Molecular Weight

291.8

Appearance

Botanical Source

Structure Type

Category

SMILES

CN(C)CCOC(C1=CC=CC=C1)C2=CC=CC=C2.Cl

Synonyms

IUPAC Name

2-benzhydryloxy-N,N-dimethylethanamine;hydrochloride

Density

1.024g/cm3

Solubility

DMSO : 100 mg/mL (342.68 mM; Need ultrasonic)
H2O : 100 mg/mL (342.68 mM; Need ultrasonic)

Flash Point

101.5ºC

Boiling Point

343.7ºC at 760 mmHg

Melting Point

168-172 °C

InChl

InChl Key

PCHPORCSPXIHLZ-UHFFFAOYSA-N

WGK Germany

RID/ADR

HS Code Reference

Personal Projective Equipment

Correct Usage

For Reference Standard and R&D, Not for Human Use Directly.

Meta Tag

provides coniferyl ferulate(CAS#:147-24-0) MSDS, density, melting point, boiling point, structure, formula, molecular weight etc. Articles of coniferyl ferulate are included as well.>> amp version: coniferyl ferulate

No Technical Documents Available For This Product.

PMID

32196480

Abstract

The objective of this project was to study the percutaneous absorption of lorazepam, diphenhydramine hydrochloride, and haloperidol from a topical Pluronic lecithin organogel, also known as ABH gel, across the porcine ear skin and verify its suitability for topical application. ABH gel was prepared using lecithin in isopropyl palmitate solution (1:1) as an oil phase and 20% w/v Poloxamer 407 solution as an aqueous phase. The gel was characterized for pH, viscosity, drug content, and thermal behavior. A robust high-performance liquid chromatography method was developed and validated for simultaneous analysis of lorazepam, diphenhydramine hydrochloride, and haloperidol. The percutaneous absorption of lorazepam, diphenhydramine hydrochloride, and haloperidol from ABH gel was carried out using Franz cells across the Strat-M membrane and pig ear skin. The pH of ABH gel was found to be 5.66 ± 0.13. The retention time of diphenhydramine hydrochloride, haloperidol, and lorazepam was found to be 5.2 minutes, 7.8 minutes, and 18.9 minutes, respectively. The ABH gel was found to be stable for up to 30 days. Theoretical steady state plasma concentrations (CSS) of diphenhydramine hydrochloride, haloperidol, and lorazepam calculated from flux values were found to be 1.6 ng/mL, 0.13 ng/mL, and 2.30 ng/mL, respectively. The theoretical CSS of diphenhydramine hydrochloride, haloperidol, and lorazepam were much lower than required therapeutic concentrations for antiemetic activity to relieve chemotherapy-induced nausea and vomiting. From the percutaneous absorption data, it was evident that ABH gel failed to achieve required systemic levels of lorazepam, diphenhydramine hydrochloride, and haloperidol following topical application.

Title

Percutaneous Absorption of Lorazepam, Diphenhydramine Hydrochloride, and Haloperidol from ABH Gel

Author

Amit Dahal # 1, Rabin Neupane # 1, Sai Hs Boddu 1 2, Jwala Renukuntla 3, Rahul Khupse 4, Richard Dudley 4

Publish date

Mar-Apr 2020;

PMID

32115530

Abstract

Diphenhydramine, a sedating antihistamine, is an agonist of human bitter taste receptor 14 (hTAS2R14). Diphenhydramine hydrochloride (DPH) was used as a model bitter medicine to evaluate whether the umami dipeptides (Glu-Glu and Asp-Asp) and their constituent amino acids (Glu, Asp) could suppress its bitterness intensity, as measured by human gustatory sensation testing and using the artificial taste sensor. Various concentrated (0.001-5.0 mM) Glu-Glu, Asp-Asp, Glu and Asp significantly suppressed the taste sensor output of 0.5 mM DPH solution in a dose-dependent manner. The effect of umami dipeptides and their constituent amino acids was tending to be ranked as follows, Asp-Asp > Glu-Glu >> Gly-Gly, and Asp > Glu >> Gly (control) respectively. Whereas human bitterness intensity of 0.5 mM DPH solution with various concentrated (0.5, 1.0, 1.5 mM) Glu-Glu, Asp-Asp, Glu and Asp all significantly reduced bitterness intensity of 0.5 mM DPH solution even though no statistical difference was observed among four substances. The taste sensor outputs and the human gustatory sensation test results showed a significant correlation. A surface plasmon resonance study using hTAS2R14 protein and these substances suggested that the affinity of Glu-Glu, Asp-Asp, Glu and Asp for hTAS2R14 protein was greater than that of Gly-Gly or Gly. The results of docking-simulation studies involving DPH, Glu-Glu and Asp-Asp with hTAS2R14, suggested that DPH is able to bind to a space near the binding position of Glu-Glu and Asp-Asp. In conclusion, the umami dipeptides Glu-Glu and Asp-Asp, and their constituent amino acids, can all efficiently suppress the bitterness of DPH.

KEYWORDS

docking simulation; human bitterness-suppressing agent; surface plasmon resonance study; taste sensor; umami-peptide.

Title

Bitterness-Suppressing Effect of Umami Dipeptides and Their Constituent Amino Acids on Diphenhydramine: Evaluation by Gustatory Sensation and Taste Sensor Testing

Author

Takayoshi Okuno 1, Shiori Morimoto 1, Haruka Nishikawa 1, Tamami Haraguchi 1, Honami Kojima 1, Hirofumi Tsujino 2, Mitsuhiro Arisawa 2, Taku Yamashita 1, Junichi Nishikawa 1, Miyako Yoshida 1, Masaaki Habara 3, Hidekazu Ikezaki 3, Takahiro Uchida 1

Publish date

2020;

PMID

32070459

Abstract

A 62-year-old patient living in a rural community was referred to participate in a pharmacist-led home visit program because of concerns with the patient’s increasing falls and medication complexity. The patient reported experiencing an increasing number of falls over the past few months, resulting in a recent hospitalization and mild head trauma. The patient’s past medical history included diabetes mellitus type 2, hypertension, hyperlipidemia, gastroesophageal reflux disease, paroxysmal atrial fibrillation, unspecified back pain, and benign prostatic hyperplasia. During the comprehensive medication review, pharmacists determined the patient had inadvertently purchased an acetaminophen/ diphenhydramine combination medication, rather than his usual acetaminophen. According to the 2019 Beers criteria, use of acetaminophen/diphenhydramine for back pain without insomnia is not the best option and may contribute to falls. With an estimated four to eight tablets per day, the patient was taking 200-400 mg of diphenhydramine daily. Pharmacist recommendations included contacting the prescribing physician to obtain a prescription for acetaminophen. By asking the local pharmacy to dispense acetaminophen as a prescription, the risk of the patient inadvertently purchasing an inappropriate product is reduced. After removing the diphenhydramine from the patient’s regimen, the falls ceased. This case demonstrates the effects of inappropriate diphenhydramine use in an especially vulnerable population. It also highlights the critical role that rural community pharmacists can play in improving their patients’ health care.

Title

Patient Fall Risk Caused by Unintended Diphenhydramine Use

Author

Kimberly C McKeirnan, Kyle R Frazier, Andrew A Yabusaki

Publish date

2020 Mar 19;